350P - Extended adjuvant temozolamide as prognostic factor of longer overall and progression-free survival in glioblastoma multiforme
| Date | 09 October 2016 |
| Event | ESMO 2016 Congress |
| Session | Poster display |
| Topics | Central Nervous System Malignancies |
| Presenter | Sara Póvoa |
| Citation | Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367 |
| Authors |
S.C. Póvoa1, N. Tavares1, M.J. Ribeiro1, D. Azevedo1, A. Coelho1, A. Fernandes1, A. Costa1, C. Caeiro1, B. Carvalho2, P. Linhares2, L. Osório3, L. Castro4, J. Fonseca5, M. Damasceno1
|
Abstract
Background
Glioblastoma multiforme (GBM), the most common malignant primary central nervous system tumour, has significant morbi-mortality. The aim is to determine prognostic factors (PF) of overall survival (OS) and progression-free survival (PFS) in patients treated with Stupp protocol.
Methods
Retrospective analysis of GBM patients ≥18 years, diagnosed from March 2004 to December 2014, treated with radiotherapy (RT) plus concomitant and adjuvant temozolomide (aTMZ). OS and PFS were assessed by Kaplan-Meier method and multivariate analysis (MA) was performed using Cox regression.
Results
A total of 213 patients completed concomitant TMZ-RT and were included in final analysis. Majority were males (n = 134), with median age of 61 years old (24-84) and 43.1% ECOG performance status 0. Gross total resection (GTR) was possible in 46.9%, partial resection in 33.3% and stereotactic biopsy (SB) in 19.7%. 197 patients proceeded to aTMZ: 107 suspended
Conclusions
Our results suggest an OS and PFS benefit of extended aTMZ beyond standard 6 cycles, with stronger impact in OS with >12 cycles. The retrospective study design limits conclusions and further validation is necessary in prospective randomized studies.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.